Foresite Capital Management VI
Latest statistics and disclosures from Foresite Capital Management VI's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGON, ALMS, Seaport Therapeutics, DNLI, CLDX, and represent 61.50% of Foresite Capital Management VI's stock portfolio.
- Added to shares of these 10 stocks: Seaport Therapeutics (+$39M), Parabilis Medicines (+$27M), CLDX (+$21M), GHRS (+$17M), JBIO (+$13M), BEAM (+$11M), CGON (+$11M), AVBP (+$11M), AGIO (+$9.6M), AURA (+$9.5M).
- Started 8 new stock positions in Kailera Therapeutics, Research Alliance Corp Iii, IRON, Parabilis Medicines, AURA, Seaport Therapeutics, BEAM, AVBP.
- Reduced shares in these 3 stocks: Centessa Pharmaceuticals (-$54M), OKUR (-$6.0M), NERV.
- Sold out of its positions in Centessa Pharmaceuticals, OKUR.
- Foresite Capital Management VI was a net buyer of stock by $117M.
- Foresite Capital Management VI has $643M in assets under management (AUM), dropping by 39.61%.
- Central Index Key (CIK): 0002013341
Tip: Access up to 7 years of quarterly data
Positions held by Foresite Capital Management VI consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Foresite Capital Management VI
Foresite Capital Management VI holds 23 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology (CGON) | 26.2 | $168M | +6% | 2.4M | 71.05 |
|
| Alumis (ALMS) | 18.6 | $120M | 4.2M | 28.14 |
|
|
| Seaport Therapeutics | 6.0 | $39M | NEW | 1.8M | 21.72 |
|
| Denali Therapeutics (DNLI) | 5.6 | $36M | +15% | 1.4M | 25.72 |
|
| Celldex Therapeutics (CLDX) | 5.1 | $33M | +178% | 880k | 37.21 |
|
| Agios Pharmaceuticals (AGIO) | 4.5 | $29M | +49% | 785k | 37.11 |
|
| Corvus Pharmaceuticals (CRVS) | 4.3 | $27M | 1.8M | 14.94 |
|
|
| Parabilis Medicines | 4.3 | $27M | NEW | 999k | 27.37 |
|
| GH Research Ord (GHRS) | 3.9 | $25M | +198% | 941k | 26.88 |
|
| Jade Biosciences (JBIO) | 3.1 | $20M | +177% | 887k | 22.22 |
|
| Hinge Health Cl A (HNGE) | 2.8 | $18M | 220k | 83.00 |
|
|
| Kymera Therapeutics (KYMR) | 2.6 | $17M | 146k | 114.67 |
|
|
| Ataibeckley (ATAI) | 2.3 | $15M | 2.8M | 5.27 |
|
|
| Verastem (VSTM) | 1.9 | $12M | 3.1M | 3.82 |
|
|
| Beam Therapeutics (BEAM) | 1.8 | $11M | NEW | 330k | 34.32 |
|
| Minerva Neurosciences (NERV) | 1.7 | $11M | 2.0M | 5.55 |
|
|
| Arrivent Biopharma (AVBP) | 1.6 | $11M | NEW | 301k | 34.74 |
|
| Aura Biosciences (AURA) | 1.5 | $9.5M | NEW | 1.3M | 7.10 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.2 | $7.9M | 212k | 37.42 |
|
|
| Research Alliance Corp III Cl A | 0.5 | $3.2M | NEW | 300k | 10.70 |
|
| Zura Bio Cl A (ZURA) | 0.4 | $2.7M | 450k | 5.90 |
|
|
| Kailera Therapeutics | 0.1 | $826k | NEW | 38k | 22.03 |
|
| Disc Medicine (IRON) | 0.0 | $71k | NEW | 970.00 | 73.14 |
|
Past Filings by Foresite Capital Management VI
SEC 13F filings are viewable for Foresite Capital Management VI going back to 2025
- Foresite Capital Management VI 2026 Q2 filed Aug. 14, 2026
- Foresite Capital Management VI 2026 Q1 filed May 15, 2026
- Foresite Capital Management VI 2025 Q4 filed Feb. 17, 2026
- Foresite Capital Management VI 2025 Q3 filed Nov. 14, 2025
- Foresite Capital Management VI 2025 Q2 filed Aug. 12, 2025